Navigation Links
Discovery of new type of immune cells regulating inflammation in chronic diseases
Date:11/20/2009

This release is available in German.

In the current online issue of the Journal of Clinical Investigation, Dr. Stefanie Eyerich and Dr. Kilian Eyerich together with their colleagues from Imperial College London and Istituto Dermopatico dell'Immacolata in Rome, present their groundbreaking discovery. It represents a milestone on the way to developing new treatment methods for inflammatory skin diseases such as psoriasis and allergic reactions and potentially also allergic respiratory diseases such as asthma.

The newly discovered Th22 cells are a previously unknown subset of T helper cells. T helper cells are white blood cells that help activate other immune cells when the body is infected by viruses or bacteria. At the same time they help the body to tolerate own tissue and to prevent or curb inflammation.

The researchers of Helmholtz Zentrum Mnchen and the Center of Allergy and Environment (ZAUM) of Technische Universitt Mnchen, together with their colleagues from London and Rome, discovered the Th22 cells while analyzing skin samples of patients with psoriasis, atopic eczema and allergic contact dermatitis. "During the histological examination we noticed T cells that were primarily characterized by the signaling molecule interleukin-22 (IL-22)," explained Dr. Stefanie Eyerich, the lead author of the study.

Th22 cells aid in tissue repair. At the same time they warn our skin cells of impending environmental dangers and stimulate the skin cells to protect themselves. In addition, they can help to strengthen the barriers of the skin and possibly also of the lung by stimulating cells to produce more collagen.

Dr. Carsten Schmidt-Weber of Imperial College London and coordinator of the study said: "We are seeing an increase in chronic diseases like skin and respiratory diseases. Besides genetic disposition, the causes are higher hygienic standards and modern nutritional habits. Diseases like psoriasis can have a substantial negative impact on a patient's quality of life, and sufferers must often follow long, drawn-out skin care treatment regimens to keep their symptoms at bay."

"We consider the discovery of the Th22 cells to be a milestone in immunology, providing a new starting point for the future treatment of chronic inflammatory diseases such as eczema, scleroderma, asthma or COPD," explained Professor Heidrun Behrendt, director of ZAUM and the Clinical Cooperation Group of Helmholtz Zentrum Mnchen and TU Mnchen.

The Munich researchers and their colleagues are elucidating the genesis of Th22 cells and investigating Th22-specific genes, which shall contribute to the development of selective and effective therapies for patients with chronic skin and respiratory diseases. Like other T helper cells, Th22 cells belong to a part of the immune system which can recognize damaging pathogens even after a long time has passed. This means that each treatment targeting these cells would have a potential long-term effect.


'/>"/>

Contact: Sven Winkler
presse@helmholtz-muenchen.de
49-089-318-73946
Helmholtz Zentrum Mnchen - German Research Center for Environmental Health
Source:Eurekalert

Related biology news :

1. Accidental discovery produces durable new blue pigment for multiple applications
2. NJIT professor to speak about discovery to Physical Society
3. Fish vision discovery makes waves in natural selection
4. Graffinity Enters into Drug Discovery Research Collaboration with Genentech
5. Milestone discovery in cell behaviors
6. Major discovery opens door to leishmania treatment
7. Genetic discovery could break wine industry bottleneck, accelerate grapevine breeding
8. UCF discovery could open door to obesity, diabetes treatments
9. Gene discovery reveals a critical proteins function in hearing
10. Discovery of genetic mutation in Leigh syndrome
11. Discovery to aid in future treatments of third-world parasites
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/6/2017)... LONDON , April 6, 2017 ... Control, RFID, ANPR, Document Readers, by End-Use (Transportation & ... Energy Facility, Oil, Gas & Fossil Generation Facility, Nuclear ... Healthcare, Educational, Other) Are you looking for ... Authentication sector? ...
(Date:4/5/2017)... , April 5, 2017 Today HYPR ... that the server component of the HYPR platform is ... providing the end-to-end security architecture that empowers biometric authentication ... HYPR has already secured over 15 million users across ... manufacturers of connected home product suites and physical access ...
(Date:4/4/2017)... NEW YORK , April 4, 2017   ... solutions, today announced that the United States Patent and ... The patent broadly covers the linking of an iris ... the same transaction) and represents the company,s 45 th ... our latest patent is very timely given the multi-modal ...
Breaking Biology News(10 mins):
(Date:4/26/2017)... Pa. , April 26, 2017  Genisphere ... delivery platform, has signed a collaborative and sponsored ... Dr. Silvia Muro . The overall goal ... and pharmacodynamics of various 3DNA designs and formulations ... involve targeting diseases of the vasculature as well ...
(Date:4/25/2017)... CA (PRWEB) , ... April 25, 2017 , ... ... of L3 Healthcare, is pleased to announce the company is now a certified ... The iMedNet software certification enables the company’s clinical research team to build, ...
(Date:4/25/2017)... Gatos, California (PRWEB) , ... April 25, 2017 ... ... business, Analytical Services and Metrology Partners.     , Covalent’s Analytical Services unit ... Most samples can be measured within 24 hours of receipt. There are no ...
(Date:4/24/2017)... 2017  Dante Labs announced today the offer of whole ... $900). While American individuals have been able to access WGS ... access WGS below EUR 1,000. The sequencing includes ... information to make informed decisions about disease monitoring, prevention, nutrition, ... ...
Breaking Biology Technology: